AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 7th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Exclusive License Agreement (this "Agreement") is made effective the 29th day of August, 2019 (the "Effective Date"), by and between Stuart Weg, MD, an individual ("Licensor"), and Seelos Therapeutics, Inc., a Delaware corporation having a principal place of business at 300 Park Avenue, 12th Floor, New York, NY 10022 ("Licensee"). Licensor and Licensee are each referred to herein individually as a "Party" and together as the "Parties".
AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 7th, 2019 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 (this "Amendment") to the Asset Purchase Agreement, dated as of March 6, 2018, by and between Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG, a stock corporation organized under the laws of Switzerland ("Seller"), and Seelos Therapeutics, Inc., a Delaware corporation ("Buyer"), as amended by that certain Amendment to Asset Purchase Agreement, dated as of May 18, 2018, by and between Buyer and Seller (as amended, the "Purchase Agreement"), is made as of December 31, 2018, by and between Buyer and Seller. Capitalized terms used but not otherwise defined herein shall have the meanings attributed to such terms in the Purchase Agreement.
